Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 26, 2419-2424, December 1, 1966]
© 1966 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gray, G. D.
Right arrow Articles by Bhuyan, B. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gray, G. D.
Right arrow Articles by Bhuyan, B. K.

Nogalamycin Effects in Rat Liver: Inhibition of Tryptophan Pyrrolase Induction and Nucleic Acid Biosynthesis1

Gary D. Gray, Gerald W. Camiener and Bijoy K. Bhuyan

Research Laboratories, The Upjohn Company, Kalamazoo, Michigan

In partially-hepatectomized and sham-operated rats, nogalamycin exhibits the same general patterns of inhibitory activity which are seen with actinomycin D: (a) Marked inhibition of orotate incorporation into RNA; (b) marked inhibition of thymidine incorporation into DNA at high drug levels only; and (c) little or no inhibition of valine incorporation into protein. Nogalamycin inhibited completely the hydrocortisone-induced increase in tryptophan pyrrolase activity but did not affect the substrate-induced increase. The inhibitory effects of nogalamycin administration were not detected after a 24-hr period. These results are compatible with the suggestion that nogalamycin interferes primarily with RNA, including messenger RNA, synthesis.

1 This work was supported in part by Contract No. SA-43-pH-1933, Cancer Chemotheraphy National Service Center.

Received 3/31/66. Accepted 6/17/66.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1966 by the American Association for Cancer Research.